title: Concentrations of progesterone, a metabolite of PGF2α, prolactin, and luteinizing hormone during development of idiopathic persistent corpus luteum in mares.
abstract: In experiment 1, daily blood samples were available from Days 0 to 20 (Day 0 = ovulation) in mares with an interovulatory interval (IOI, n = 5) and in mares that developed idiopathic persistent corpus luteum (PCL, n = 5). The PCL was confirmed by maintenance of progesterone (P4) concentration until end of the experiment (Day 20). Significant interactions of group and day revealed the novel findings that luteinizing hormone (LH) was lower (P < 0.05) in the PCL group than that in the IOI group on Days 0 to 4, and prolactin was lower (P < 0.05) on Days 1, 4, 6, and 7. In experiment 2, treatment with a gonadotropin-releasing hormone antagonist (n = 6) significantly reduced LH on Days 1 to 6 compared with the controls (n = 6) but did not support the hypothesis that low LH during the postovulatory period increases the frequency of PCL. In experiment 3, P4, PGFM (a PGF2α metabolite), and prolactin concentrations on Days 12 to 20 from 2 reported experiments were combined to increase the number of mares with an IOI (n = 11) or a PCL (n = 11). An abrupt and complete decrease in P4 (luteolysis) began on Day 13 in the IOI group compared with a gradual and partial P4 decline after Day 12 in the PCL group. Concentrations of PGFM and prolactin were lower (P < 0.05) in the PCL group than those in the IOI group on the day at the end of the most pronounced decrease in P4. The PCL mares were subgrouped into those with an abrupt but incomplete P4 decrease (partial luteolysis; n = 5) at the expected time and those without partial luteolysis (n = 6). There were no significant differences between the 2 subgroups in concentrations of PGFM and prolactin, but on a tentative basis (P < 0.10), the concentration of PGFM seemed more focused on the day of the most pronounced decrease in P4 in the subgroup with partial luteolysis. Results for PCL compared with IOI indicated (1) postovulatory LH and prolactin were lower, (2) treatment to reduce postovulatory LH did not increase the incidence, and (3) both PGFM and prolactin were lower on the day of the most pronounced decrease in P4.
authors.affiliation: Eutheria Foundation, Cross Plains, WI 53528, USA; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA. Electronic address: oginther@wisc.edu.
authors.forename: O J
authors.initials: OJ
authors.lastname: Ginther
authors.affiliation: Eutheria Foundation, Cross Plains, WI 53528, USA; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Baldrighi
authors.affiliation: Eutheria Foundation, Cross Plains, WI 53528, USA; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA.
authors.forename: T
authors.initials: T
authors.lastname: Castro
authors.affiliation: Eutheria Foundation, Cross Plains, WI 53528, USA; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA; CAPES Foundation, Ministry of Education of Brazil, Brasilia-DF, 70040-020, Brazil.
authors.forename: C A
authors.initials: CA
authors.lastname: Wolf
authors.affiliation: Eutheria Foundation, Cross Plains, WI 53528, USA; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA.
authors.forename: V G
authors.initials: VG
authors.lastname: Santos
mesh_terms: D000818:Animals; D003338:Corpus Luteum / Q000378:metabolism*; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism; D005260:Female; D006734:Horse Diseases / Q000097:blood*; D006736:Horses; D007986:Luteinizing Hormone / Q000097:blood*; D003341:Luteolysis / Q000502:physiology; D009842:Oligopeptides / Q000494:pharmacology; D010060:Ovulation / Q000187:drug effects / Q000502:physiology; D011374:Progesterone / Q000097:blood / Q000378:metabolism*; D011388:Prolactin / Q000097:blood*
chemical_list: D009842:Oligopeptides; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D011374:Progesterone; D011388:Prolactin; D007986:Luteinizing Hormone; D015237:Dinoprost; C109238:acyline
keywords: Luteinizing hormone; PGF2α; Persistent corpus luteum; Progesterone; Prolactin